Mach 1 Financial Group LLC Has $4.08 Million Stock Position in Eli Lilly and Company $LLY

Mach 1 Financial Group LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 171.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,792 shares of the company’s stock after acquiring an additional 2,394 shares during the period. Eli Lilly and Company makes up approximately 0.8% of Mach 1 Financial Group LLC’s portfolio, making the stock its 27th biggest position. Mach 1 Financial Group LLC’s holdings in Eli Lilly and Company were worth $4,075,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC boosted its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in shares of Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $356,000. Finally, Nebula Research & Development LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Bank of America reduced their price objective on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage Phase 3 data for Lilly’s experimental weight-loss drug retatrutide showed dramatic results, with patients losing about 28% of body weight on average over 80 weeks, strengthening the case for a future approval and expanding Lilly’s obesity pipeline. Article Title
• Positive Sentiment: CNBC reported that retatrutide cleared a crucial obesity trial, moving Lilly one step closer to seeking approval for what could become another major blockbuster in the GLP-1/obesity market. Article Title
• Positive Sentiment: The New York Times highlighted the same retatrutide results, reinforcing investor optimism that Lilly can keep dominating the rapidly growing weight-loss-drug category. Article Title
• Positive Sentiment: Reuters said lower-priced Lilly and Novo Nordisk obesity pills are drawing patients away from compounded alternatives, suggesting branded products are gaining share and supporting longer-term commercial demand. Article Title
• Neutral Sentiment: Lilly also completed an $8.9 billion debt offering and acquired Engage Biologics for up to $202 million, moves that support pipeline expansion but may also modestly increase financing and integration costs. Article Title
• Neutral Sentiment: Reports on Lilly’s TuneLab AI partnership and broader R&D recognition are supportive of the company’s innovation story, but they are less likely to move the stock than the obesity-trial headlines. Article Title
• Negative Sentiment: Separately, Lilly disclosed a lawsuit alleging more than $200 million in Trulicity rebate fraud, which is a legal overhang, though it is not the main driver of today’s sentiment. Article Title

Eli Lilly and Company Trading Down 0.5%

LLY opened at $1,016.05 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a fifty day moving average of $940.69 and a 200-day moving average of $1,002.07. The stock has a market cap of $956.85 billion, a PE ratio of 36.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the company posted $3.34 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.